Remove Article Remove Chemotherapy Remove Immunization
article thumbnail

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

Drug Topics

Currently it’s going to be slowing to upper single digits through the forecast period, basically because 2 of the leading drugs, there's immune checkpoint inhibitors—nivolumab is the molecule—and pembrolizumab is Keytruda, 2 of those are going off patent in 2028 and 2029. That trend is in the low-to-mid teens in terms of growth rate.

article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

Published July 8, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 5 min This audio is auto-generated. You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.

article thumbnail

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Pharmacy Times

SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Acalabrutinib plus bendamustine and rituximab may become new standard care for untreated MCL.

FDA
article thumbnail

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Offering and promoting immunizations and point-of-care testing are 2 proven ways to address SDOH.

article thumbnail

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. N Engl J Med. 2019;380:2020-2030. Subscribe Now!